So, now if anyone out there doesn't want to focus
Post# of 30028
AMBSDX spin off into what type of company? Public on the market? Nasdaq? We will have Multi-Billion dollar stand alone Diagnostic (LymPro Test®) that does nothing but essentially collects money.
If we end up doing a "Traditional. Partnership" with ICON, say 80 - 20% ( for voting rights, tax breaks & Dividens ) which we would need for a Holding company and in the "Partnership" also guarantee ICON a piece of NuroPro® Blood Test, which they will be helping us with, They would then have the same set up with 2 multi Billion dollars DX tests.
And, if PhenoGuard has found another protein than in GC's words it, we can license the Platform out and or license the New protein out ....
The discovery of another such protein family would transform PhenoGuard into the first ever rationally-designed neurotrophic factor discovery platform, a tremendously valuable asset for high science companies. - See more at: http://www.thechairmansblog.com/amarantus-bio...TWpqI.dpuf
Coupled with our partnering business model, we believe we will be able to find the appropriate partner for PhenoGuard to fully exploit the true value of this technology. - See more at: http://www.thechairmansblog.com/amarantus-bio...i0yNz.dpuf
If they are willing to pay X now, could pay 100X down the road. What would be the price to Buy LymPro Test® ? To keep it from all other competition? Once it shows what it can do. And if we sell LP, we can still generate 1+ Billion with NuroPro® Blood Test AND still have or DX company intact.
Absolutely no way, do I believe GC would sell AMBS or AMBS DX! And certainly not for a years earning of just one product a year out from now.
Sure a difficult day for some, but what is your tolerance level, what is your timeline and what is your goal.